Novo Nordisk A/S (NVO)
-NYSE 161.70 Jun 17, 4:02PM EDT
| Prev Close: | 161.70 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 199.15 |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 135.77 - 194.44 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 268,908 |
|---|
| Market Cap: | 87.58B |
|---|
| P/E (ttm): | 22.43 |
|---|
| EPS (ttm): | 7.21 |
|---|
| Div & Yield: | 2.26 (1.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)at Motley Fool(Sat, Jun 15)
- Encouraging Data on Novartis' GilenyaZacks(Fri, Jun 14)
- Lilly Alzheimer's Study TerminatedZacks(Fri, Jun 14)
- China Biologic: A Star Small-Cap Pick From Chinaat Seeking Alpha(Thu, Jun 13)
- Sanofi's Fluzone Quadrivalent Gets FDA NodZacks(Thu, Jun 13)
- 3 Drug Manufacturers With Encouraging Receivablesat Seeking Alpha(Wed, Jun 12)
- Tme to Buy This Defensive Growth Stock?at Motley Fool(Wed, Jun 12)
- Novo Nordisk Is An Undervalued Industry Leading Healthcare Companyat Seeking Alpha(Wed, Jun 12)
- CHMP Positive on Sanofi's LantusZacks(Tue, Jun 11)
- Novo Nordisk A/S (NVO): Today's Featured Drugs Winnerat TheStreet(Tue, Jun 11)
- 4 Stocks Boosting The Drugs Industry Higherat TheStreet(Tue, Jun 11)
- This Under-The-Radar Diabetes Stock Has Significant Upside Potentialat Seeking Alpha(Tue, Jun 11)
- FDA Panel Positive on GSK's AvandiaZacks(Fri, Jun 7)
- World's Largest Chemical Company Makes a Splash in Enzymesat Motley Fool(Fri, Jun 7)
- Avandia Vote Ends An Era Of Drug Safety Scandalsat Forbes(Thu, Jun 6)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| NVO | 0.00% | 87.58B |
| TEVA | 0.00% | 33.50B |
| AGN | 0.00% | 30.08B |
| FRX | 0.00% | 11.01B |
Key Statistics
| Forward P/E (1 yr): | 19.79 |
|---|
| P/S (ttm): | 6.29 |
|---|
| Ex-Dividend Date: | 21-Mar-13 |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(Jun-12)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals.
View More 
0.73%